Drug Trial Radar · NCT05059509
Evaluate Efficacy of FB825 in Adults With Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Apr 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Feb 6, 2020
Primary completion
May 10, 2021
Study completion Mar 31, 2022
Sponsor
- Lead sponsor
- Oneness Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open labeled exploratory study to evaluate efficacy of FB825 in adults with atopic dermatitis (AD). The study will be conduct at one medical center in Taiwan. Approximately 20 subjects with atopic dermatitis (AD), who meet the criteria for study entry, will be enrolled to the study. All eligible subjects will receive FB825, 5mg/kg, by 1 hour IV infusion on Day 1. Subjects will return to the study site on Days 15, 29 and 57 for the safety and efficacy evaluation. Subjects who premature withdraw from the study will have an end of study (EOS) visit within 7 days.
Conditions
- Atopic Dermatitis
Interventions
FB825Biological
FB825, 5mg/kg, by 1 hour IV infusion on Day 1
Primary outcomes
What the sponsor says the trial is designed to measure.
- The mean change in mIgE (Membrane bound Immunoglobulin E) B cell count (absolute and percentage) from baselineTime frame: week 2 and 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Taiwan University Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.